Pet Wellness Isn't Human Wellness Running 10 Years Late — It's Harder Than That

Key insights

• The global pet dietary supplements market is projected to grow from $4.76 billion in 2025 to $7.31 billion by 2031, at a CAGR of 7.42%, per Mordor Intelligence — driven by both premiumization and rising ingredient and logistics costs
• Japan's pet food market is forecast to expand from ¥720 billion in 2024 to ¥1.27 trillion by 2033, per IMARC Group — growth powered by per-animal spending increases, not headcount growth
• Probiotics and prebiotics remain the dominant functional ingredient categories in pet supplements; postbiotics represent the fastest-growing niche, not yet the mainstream
• Species-specific safety trials and regulatory compliance (AAFCO in the US, FEDIAF in Europe) are required for each functional ingredient claim — human clinical evidence does not transfer directly to companion animal formulations

The pet wellness market is expanding, but the story behind the numbers is less straightforward than most market reports suggest. Rising ingredient and logistics costs are inflating per-unit prices alongside genuine consumer premiumization — which means headline growth figures overstate how much of the expansion reflects new willingness to spend versus prices simply going up. The market is also bifurcating: the ultra-premium functional tier and the budget tier are both growing, while the middle is eroding. Per-animal spending is increasing in Japan while total pet ownership is flat or slightly declining — growth is coming from deeper investment in fewer animals, not from more animals being owned. And the functional ingredient categories driving that spending are, in order of actual market share, still glucosamine, omega-3s, probiotics, and prebiotics — with postbiotics emerging as a significant R&D direction but not yet a mainstream product category.

Pet Owners Are Spending More Per Animal — But Inflation and Bifurcation Are Part of the Story

The "healthspan" reframe — from extending life to improving quality of life across its full length — is a genuine shift in how pet owners think about nutrition, documented by Glanbia Nutritionals as a megatrend in its 2026 functional nutrition analysis. Mintel confirmed the market effect: more than 50% of new human dietary supplement products launched since July 2024 now carry at least one healthspan claim, and the same logic is arriving in the pet aisle. But consumer consciousness is not the only driver of rising market values.

IMARC Group and Mordor Intelligence both identify raw material cost inflation and logistics cost increases as significant contributors to the market's expanding dollar value — meaning a portion of what reads as "market growth" in headline figures is price inflation embedded in existing products, not new demand. The practical effect is a market sorting into two tiers: an ultra-premium segment where pet owners with high willingness-to-pay are upgrading to condition-specific functional formulations, and a budget segment where cost-conscious owners are trading down. The middle tier — standard premium pet food without specific functional claims — is the segment under the most pressure. Specialty and wellness sales grew 16.6% in 2025, per Numerator, while overall pet sector spending growth moderated to 2.9%. That divergence reflects bifurcation, not a uniform shift upmarket.

Japan is the clearest example of the per-animal spending dynamic. Total pet ownership in Japan is flat to slightly declining — the market's expansion from ¥720 billion to a projected ¥1.27 trillion by 2033 is driven by increased spending per animal, not by more animals being owned, per IMARC Group. Cat food volumes are approaching parity with dog food in several segments, reflecting a shift in species mix rather than net headcount growth. The aging, single-person household structure that has elevated pets to primary companionship does support higher per-animal health investment — but it also has an economic limit. The household that treats one cat as a family member can spend significantly more per animal; it cannot do so indefinitely, and that ceiling has not yet been stress-tested in a sustained economic downturn.

Postbiotics Are an R&D Direction, Not Yet the Market Standard — and the Validation Gap Is Real

The functional pet supplement category is often described through its most technically advanced products — a framing that obscures where the actual market volume sits. Glucosamine still holds a 37.24% share of the global pet dietary supplements market in 2025, per Fortune Business Insights. Probiotics and prebiotics are the fastest-growing mainstream segment, projected at a 10.5% CAGR through 2031, per Mordor Intelligence. Postbiotics — short-chain fatty acids including butyrate, propionate, and acetate — are being incorporated into companion animal formulations in 2026, per ShareShima's analysis of the Japanese pet food ingredients market, and represent a significant emerging direction. They are not yet a mass-market category.

The distinction matters because the path from emerging to mainstream in pet supplements is longer and more regulated than in human wellness. Cats lack the glucuronidation metabolic pathway that processes many compounds safely in humans and dogs; what is well-tolerated in a human probiotic formulation may be ineffective or contraindicated in a feline one. Dogs and cats also differ meaningfully from each other in how they metabolize short-chain fatty acids, omega-3 precursors, and botanical extracts. Each functional ingredient requires species-specific safety trials and efficacy evidence before it can be claimed in a commercial product — a requirement that applies regardless of whether the ingredient is sourced to human-grade standards. Human-grade supply chains, which TOMORUBA's market analysis identifies as a defining structural shift in the Japanese pet food market, address ingredient quality. They do not substitute for species-specific validation.

This is the variable most market-sizing reports underweight. AAFCO standards in the US and FEDIAF guidelines in Europe govern what can be claimed in animal nutrition, and the clinical evidence base for postbiotics and adaptogens in companion animals remains substantially thinner than the human equivalents. The gap between "ingredient is being incorporated" and "ingredient has regulatory-compliant efficacy claims" is where most emerging functional pet products currently sit.

What Mars and Nestlé Are Actually Building — and Why It Isn't Simply the Human Playbook

The framing that Mars Petcare and Nestlé's Purina PetCare are running the human functional food playbook on companion animals a decade later is useful as a marketing narrative. It is not accurate as a description of their R&D investment. Both companies are investing in pet-specific microbiome research — analyzing the companion animal biome as a distinct biological system, not as a derivative of human gut health data. Royal Canin, the veterinary nutrition brand owned by Mars Petcare, operates dedicated veterinary research centers focused on breed-specific and species-specific formulation science. This is not human ingredient science adapted for pets; it is pet-specific biology being studied on its own terms.

The competitive advantage this creates is not brand recognition or distribution, though both matter. It is the veterinary R&D infrastructure required to generate species-specific evidence — the evidence that regulatory compliance, veterinary endorsement, and credible functional claims require. A food, beauty, or supplement brand that has built functional ingredient credibility in the human wellness category cannot repackage that credibility for pets. The validation pipeline must be rebuilt from scratch for each species, each ingredient, and each claim. Smaller entrants can access the same raw ingredients; they cannot easily replicate the validation infrastructure that sits behind them.

Japan's pet wellness market is already mainstream — growing in per-animal spending terms at a pace its broader consumer economy cannot match, and technically further advanced than most Western observers recognize. The $7.31 billion projected for the global pet dietary supplements market by 2031 represents a real opportunity. But the entry cost is not simply a question of timing or consumer insight. Brands that enter with species-validated formulations, regulatory compliance, and veterinary evidence will be positioned to capture value from that growth. Brands that enter with demand insight and human-derived ingredient assets, without the species-specific validation infrastructure, will find that the barrier is the same one the incumbents spent decades building.